Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 7:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 573 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Novo Nordisk A/S Clear all
Completed No phase listed Observational

GAPP 2 Survey: Global Attitudes of Patients and Physicians in Insulin Therapy for Type 2 Diabetes Mellitus

NCT01950637
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
No treatment given, survey
Behavioral
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
Not listed
Enrollment
4,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 13, 2017 · Synced Oct 14, 2026, 7:10 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to SGLT-2i in Subjects With Type 2 Diabetes Mellitus

NCT03086330
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
Semaglutide, Placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
43
States / cities
Andalusia, Alabama • Anniston, Alabama • Glendale, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2021 · Synced Oct 14, 2026, 7:10 AM EDT
Completed Phase 3 Interventional Results available

The Efficacy and Safety of Liraglutide Adjunct to Insulin Treatment in Type 1 Diabetes

NCT02098395
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 1
Interventions
liraglutide, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
835 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
47
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Concord, California + 43 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2017 · Synced Oct 14, 2026, 7:10 AM EDT
Completed Phase 3 Interventional

A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight

NCT06131437
View directory record Official record
Conditions
Obesity
Interventions
Cagrilintide, Semaglutide, Tirzepatide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
809 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
46
States / cities
Birmingham, Alabama • Montgomery, Alabama • Costa Mesa, California + 39 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Oct 14, 2026, 7:10 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Children and Adolescents With Type 1 Diabetes

NCT02670915
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 1
Interventions
Faster-acting insulin aspart, insulin aspart, insulin degludec
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
1 Year to 17 Years
Enrollment
834 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
38
States / cities
Phoenix, Arizona • Tucson, Arizona • Long Beach, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2019 · Synced Oct 14, 2026, 7:10 AM EDT
Completed Phase 3 Interventional Results available

STEP 1: Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity

NCT03548935
View directory record Official record
Conditions
Metabolism and Nutrition Disorder, Overweight or Obesity
Interventions
Semaglutide, Placebo (semaglutide)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
1,961 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
39
States / cities
Anniston, Alabama • Anaheim, California • Lomita, California + 32 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2021 · Synced Oct 14, 2026, 7:10 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy of NovoLog vs. Humalog in Insulin Pumps in Children and Adolescents

NCT00097071
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 1
Interventions
insulin lispro, insulin aspart
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
3 Years to 18 Years
Enrollment
299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
52
States / cities
Mobile, Alabama • Montgomery, Alabama • Phoenix, Arizona + 44 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2016 · Synced Oct 14, 2026, 7:10 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Insulin Degludec/Insulin Aspart in Insulin-naïve Subjects With Type 2 Diabetes Using Two Dosing Regimens

NCT01365507
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin degludec/insulin aspart
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
25
States / cities
Concord, California • Los Angeles, California • Montclair, California + 20 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2017 · Synced Oct 14, 2026, 7:10 AM EDT
Completed Phase 3 Interventional Results available

A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) in Subjects With Type 2 Diabetes Mellitus Using Two Different Titration Algorithms

NCT02298192
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin degludec/liraglutide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
40
States / cities
Hamilton, Alabama • Chandler, Arizona • Glendale, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated May 23, 2017 · Synced Oct 14, 2026, 7:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

First Research Study of the Possible New Medicine NNC0113-2023 in Healthy Men.

NCT03617081
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
NNC0113-2023, Placebo (NNC0113-2023)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 10, 2020 · Synced Oct 14, 2026, 7:10 AM EDT
Completed Phase 3 Interventional

A Research Study Investigating Mim8 in Adults and Adolescents With Haemophilia A With or Without Inhibitors

NCT05053139
View directory record Official record
Conditions
Haemophilia A, Haemophilia A With Inhibitors
Interventions
NNC0365-3769 (Mim8)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
12 Years and older
Enrollment
281 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
34
States / cities
Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 28 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2025 · Synced Oct 14, 2026, 7:10 AM EDT
Completed Phase 1 Interventional

A Research Study of NNC0165-1562 and Semaglutide in People Who Are Overweight or Obese

NCT03574584
View directory record Official record
Conditions
Metabolism and Nutrition Disorders, Overweight or Obesity
Interventions
NNC0165-1562, Semaglutide, Placebo (NNC0165-1562)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
19 Years to 55 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
2
States / cities
Tempe, Arizona • Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jul 2, 2021 · Synced Oct 14, 2026, 7:10 AM EDT
Completed Phase 3 Interventional Results available

A Research Study in Children With a Low Level of Hormone to Grow. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day (REAL4)

NCT03811535
View directory record Official record
Conditions
Growth Hormone Deficiency in Children
Interventions
Somapacitan, Norditropin®
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
Up to 11 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
27
States / cities
Birmingham, Alabama • Los Angeles, California • Madera, California + 24 more
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 14, 2026, 7:10 AM EDT
Terminated Not applicable Interventional Results available

Duration of The Honeymoon Phase of Type 1 Diabetes: A Comparison of Insulins Detemir, Glargine and NPH

NCT00564018
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Insulin detemir, Glargine, NPH
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
6 Years to 18 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 11, 2019 · Synced Oct 14, 2026, 7:10 AM EDT
Active, not recruiting Phase 3 Interventional

A Research Study to Compare Somapacitan Once a Week With Norditropin® Once a Day in Children Who Need Help to Grow

NCT05330325
View directory record Official record
Conditions
SGA, Turner Syndrome, Noonan Syndrome, ISS
Interventions
Somapacitan, Norditropin®
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
2 Years to 10 Years
Enrollment
412 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
35
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 14, 2026, 7:10 AM EDT
Completed Phase 2 Interventional Results available

Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity.

NCT03856047
View directory record Official record
Conditions
Overweight, Obesity
Interventions
NNC0174-0833, Placebo (NNC0174-0833), Liraglutide 3.0 mg, Placebo (Liraglutide 3.0 mg)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
706 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
22
States / cities
Anaheim, California • Spring Valley, California • Crystal River, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2024 · Synced Oct 14, 2026, 7:10 AM EDT
Completed Phase 2 Interventional Results available

A Trial Evaluating Efficacy and Safety of Prophylactic Administration of Concizumab in Patients With Severe Haemophilia A Without Inhibitors

NCT03196297
View directory record Official record
Conditions
Haemostasis, Haemophilia A
Interventions
Concizumab, Turoctocog alfa
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older · Male only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
5
States / cities
Los Angeles, California • Indianapolis, Indiana • Oklahoma City, Oklahoma + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2021 · Synced Oct 14, 2026, 7:10 AM EDT
Completed Phase 3 Interventional Results available

Dual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Subjects With Type 2 Diabetes

NCT01336023
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin degludec/liraglutide, insulin degludec, liraglutide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
1,663 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
146
States / cities
Birmingham, Alabama • Anaheim, California • Bermuda Dunes, California + 126 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2018 · Synced Oct 14, 2026, 7:10 AM EDT
Completed Phase 4 Interventional Results available

Long Term Comparative Effectiveness of Once Weekly Semaglutide Versus Standard of Care in a Real World Adult US Population With Type 2 Diabetes - a Randomized Pragmatic Trial

NCT03596450
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Semaglutide, Standard of care
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,278 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
180
States / cities
Buena Park, California • Burbank, California • Costa Mesa, California + 144 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 14, 2026, 7:10 AM EDT
Completed Phase 3 Interventional Results available

A Trial Evaluating Compatibility and Safety of FIAsp and Insulin Aspart With an External Continuous Subcutaneous Insulin Infusion System in Adult Subjects With Type 1 Diabetes

NCT01999322
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 1
Interventions
Faster-acting insulin aspart, insulin aspart
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 31, 2017 · Synced Oct 14, 2026, 7:10 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Impact of Liraglutide 3.0 on Body Fat Distribution

NCT03038620
View directory record Official record
Conditions
Obesity, Visceral, Cardiovascular Diseases, Fat Disorder
Interventions
Liraglutide, Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
35 Years and older
Enrollment
235 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 19, 2021 · Synced Oct 14, 2026, 7:10 AM EDT
Completed No phase listed Observational

Pharmacodynamics of CNP During Growth Hormone Treatment

NCT01504802
View directory record Official record
Conditions
Pituitary Dwarfism, Idiopathic Short Stature
Interventions
Not listed
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
3 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
2
States / cities
Los Angeles, California • Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 2, 2014 · Synced Oct 14, 2026, 7:10 AM EDT
Completed Phase 3 Interventional Results available

Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in People Who Are Overweight or Living With Obesity (OASIS 1)

NCT05035095
View directory record Official record
Conditions
Obesity, Overweight
Interventions
Oral semaglutide, Placebo (semaglutide)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
667 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
13
States / cities
Birmingham, Alabama • Los Angeles, California • Kissimmee, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Oct 14, 2026, 7:10 AM EDT
Completed Phase 2 Interventional

A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Help People With Excess Body Weight Lose Weight

NCT06326060
View directory record Official record
Conditions
Obesity
Interventions
NNC0519-0130, Placebo, Tirzepatide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
354 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
49
States / cities
Mesa, Arizona • Little Rock, Arkansas • Searcy, Arkansas + 40 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 14, 2026, 7:10 AM EDT